Evidence map›Paper›PMID 32494975›Full record

ArticlePsychopharmacology2020

Effects of the cannabinoid receptor agonist CP-55,940 on incentive salience attribution.

Ali Gheidi, Lora M Cope, Christopher J Fitzpatrick, Benjamin N Froehlich, Rachel Atkinson, Coltrane K Groves, Clair N Barcelo, Jonathan D Morrow

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Psychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Decreased Ventral Tegmental Area CB1R Signaling Reduces Sign Tracking and Shifts Cue-Outcome Dynamics in Rat Nucleus Accumbens.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ali GheidiDepartment of Psychiatry, University of Michigan, Ann Arbor, USA.
Lora M CopeDepartment of Psychiatry, University of Michigan, Ann Arbor, USA.
Christopher J FitzpatrickNeuroscience Graduate Program, University of Michigan, Ann Arbor, USA.
Benjamin N FroehlichDepartment of Psychiatry, University of Michigan, Ann Arbor, USA.
Rachel AtkinsonDepartment of Psychiatry, University of Michigan, Ann Arbor, USA.
Coltrane K GrovesDepartment of Psychiatry, University of Michigan, Ann Arbor, USA.
Clair N BarceloMolecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, USA.
Jonathan D MorrowDepartment of Psychiatry, University of Michigan, Ann Arbor, USA. jonmorro@umich.edu.ORCID http://orcid.org/0000-0002-3530-4544
University of Michigan · US

Funding

POSTDOCTORAL TRAINING IN THE BIOLOGY OF DRUG ABUSET32DA007268 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TRAYNOR, JOHN R. · 1991 to 2021
$6.7M
NIDA Training Program in Neuroscience-Administrative SupplementT32DA007281 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Shelly Beth Flagel · 1995 to 2026
$5.7M
Individual Differences in Epigenetic Regulation of Emotional LearningR01DA044960 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MORROW, JONATHAN DAVID · 2018 to 2022
$2.3M
Neural Circuitry of Shared Vulnerability to Both PTSD and AddictionK08DA037912 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MORROW, JONATHAN DAVID · 2014 to 2018
$940k
Multi-method signature of risk for compulsive substance use: Human translation of the incentive-sensitization modelK01DA044270 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI COPE, LORA M. · 2019 to 2023
$835k
Brain and Behavior Research Foundation 20829NIDA NIH HHS DA007281NIDA NIH HHS DA037912NIDA NIH HHS DA044270NIDA NIH HHS DA044961NIDA NIH HHS DA07268NIDA NIH HHS K01 DA044270NIDA NIH HHS K08 DA037912NIDA NIH HHS R01 DA044960NIDA NIH HHS T32 DA007268NIDA NIH HHS T32 DA007281
6 · The paper itself

Abstract

rationalePavlovian conditioned approach paradigms are used to characterize the nature of motivational behaviors in response to stimuli as either directed toward the cue (i.e., sign-tracking) or the site of reward delivery (i.e., goal-tracking). Recent evidence has shown that activity of the endocannabinoid system increases dopaminergic activity in the mesocorticolimbic system, and other studies have shown that sign-tracking behaviors are dependent on dopamine.

objectivesTherefore, we hypothesized that administration of a cannabinoid agonist would increase sign-tracking and decrease goal-tracking behaviors.

methodsForty-seven adult male Sprague-Dawley rats were given a low, medium, or high dose of the cannabinoid agonist CP-55,940 (N = 12 per group) or saline (N = 11) before Pavlovian conditioned approach training. A separate group of rats (N = 32) were sacrificed after PCA training for measurement of cannabinoid receptor type 1 (CB1) and fatty acid amide hydrolase (FAAH) using in situ hybridization.

resultsContrary to our initial hypothesis, CP-55,940 dose-dependently decreased sign-tracking and increased goal-tracking behavior. CB1 expression was higher in sign-trackers compared with that in goal-trackers in the prelimbic cortex, but there were no significant differences in CB1 or FAAH expression in the infralimbic cortex, dorsal or ventral CA1, dorsal or ventral CA3, dorsal or ventral dentate gyrus, or amygdala.

conclusionsThese results demonstrate that cannabinoid signaling can specifically influence behavioral biases toward sign- or goal-tracking. Pre-existing differences in CB1 expression patterns, particularly in the prelimbic cortex, could contribute to individual differences in the tendency to attribute incentive salience to reward cues.

Indexed as

AmygdalaAnalgesicsAnimalsCannabinoid Receptor AgonistsConditioning, ClassicalCyclohexanolsDose-Response Relationship, DrugMaleMotivationRatsRats, Sprague-DawleyReceptor, Cannabinoid, CB13-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanolAnalgesicsCannabinoid Receptor AgonistsCyclohexanolsReceptor, Cannabinoid, CB1AddictionFatty acid amide hydrolaseGoal-trackingIn situ hybridizationPavlovian conditioningRatReward learningSign-tracking

Identifiers

PMID32494975
PMCPMC7502542
OpenAlexW3029350559

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.